Skip to main content
x

The Neurelis Board of Directors are
Dedicated to Achieving Progress

Our board of directors have the relevant experience needed to help a specialty pharmaceutical company thrive.

Dr. Priyanka Belawat 

Director

D r. Priyanka Belawat is an Investment Advisor for HBM Healthcare Investments.  Dr. Belawat has 10 years of experience in venture and private equity investing in the healthcare space. She has been instrumental in many portfolio investments of HBM funds in areas of biotech, pharma diagnostics and services. Presently, she represents HBM funds on the board of Neurelis Inc., and is board observer to ARMO Biosciences (USA, Immuno-oncology), TrueNorth Therapeutics (USA, Rare diseases), SAI Lifesciences (India, Contract research and manufacturing), and 1MG (India, Online pharma portal). She was closely involved with HBM’s investment in Advanced Accelerator Applications (NASDAQ:AAAP), a French company in the radio-therapeutics and radio-diagnostics space, which went public at US NASDAQ in 2014. She also has extensive knowledge of the Indian pharma sector and has been involved in various public equity, fund, and direct private investments in India.
 
Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and completed post-doctorate work at HKUST.

STEVE CARTT

Director

S teve Cartt joined Neurelis as a board member in January 2020. He previously served as President and CEO of Asterias Biotherapeutics and was a board member from 2016 until its acquisition in 2019 by BioTime, Inc., where he previously was a board member from 2014 to 2016.
 
Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals, Inc., from 2012 to 2014 until the company was acquired by Mallinckrodt plc. Mr. Cartt served as Chief Operating Officer of the Autoimmune and Rare Diseases business unit of Mallinckrodt plc on an interim basis in 2014 following the merger with Questcor. He originally joined Questcor as Executive Vice President, Corporate Development, in 2005. He was later appointed Chief Business Officer and then Chief Operating Officer. Mr. Cartt was a private consultant from 2002 to 2005. Between 2000 and 2002, he was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Prior to that, Mr. Cartt held a variety of R&D and commercial positions at ALZA Corporation from 1985 to 2000.
 
Mr. Cartt holds a BS degree from the University of California at Davis in biochemistry, and an MBA from Santa Clara University.

Craig C. Chambliss 

President and CEO/Co-Founder

C raig Chambliss has 25 years invested in the pharmaceutical, biotechnology, and drug delivery arenas, with primary focus on diseases of the central nervous system (CNS) and epilepsy, in particular. He co-founded Neurelis in 2007 and has served as CEO and President since 2013.
 
In 2010, Mr. Chambliss joined NextWave Pharmaceuticals as Chief Business Officer and directed the corporate refocus to the CNS market, raising $45M in Series C financing and culminating in the sale of NextWave to Pfizer for over $700M in 2012. Prior to NextWave and Neurelis, he led commercial operations at Questcor Pharmaceuticals, from 2005-2007, where he was responsible for helping to engineer the transition to a CNS-focused company and establish the commercial infrastructure to support the relaunch of Acthar® Gel (repository corticotropin injection).
 
Mr. Chambliss began his career in pharmaceutical sales at Bristol-Myers Squibb and joined Alza Pharmaceuticals upon the launch of their commercial organization in 1994. While at Alza Pharmaceuticals, he served in various sales and marketing roles prior to joining Elan Pharmaceuticals where he served as Director of Business Development for CNS assets. In 2001, along with other former Dura and Elan executives, Mr. Chambliss launched Xcel Pharmaceuticals, a CNS start-up focused on epilepsy and, primarily, the treatment of acute repetitive seizures. He led commercial operations and the successful launch of Diastat® (diazepam rectal gel) until Xcel's acquisition by Valeant Pharmaceuticals in 2005 for $280M. Mr. Chambliss holds a BS in Finance and a BS in Accounting from Missouri State University.

David F. Hale

Director/Co-Founder

D avid Hale is a co-founder and Director of Neurelis.  He is Chairman and CEO of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as Chairman of 2 public companiesBiocept, Inc., a cancer diagnostic company, and Conatus Pharmaceuticals, Inc., a liver disease companyand is on the board of Cassiopea, a dermatology company. He served as Chairman of Santarus, Inc., prior to its sale to Salix Pharmaceuticals, Inc. in 2014; SkinMedica, Inc., prior to its sale to Allergan in 2012; Micromet, Inc., prior to its sale to Amgen Inc. in 2012; Somaxon Pharmaceuticals prior to its sale to Pernix in 2013; and Crisi Medical Systems prior to its sale to Becton-Dickinson in 2015.
 
Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies. He is a co-founder and Chairman of Advantar Laboratories, Inc., Agility Clinical, Inc., MDRejuvena, Inc., Skylit, Inc., Recros Medica, and a co-founder and Managing Member of Dermata Therapeutics, LLC. He is also Chairman of Colorescience, Inc., and Ridge Diagnostics, Inc. He was also a co-founder of Cadence, Evoke, Elevation, and Zogenix. 
 
In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, Mr. Hale served as COO and President, and then Chief Executive Officer when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President, and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., and was then acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc.  In 1997, he was a co-founder and served as Chairman of LMA North America until its merger with LMA International in 2004. He was President and CEO of Women First HealthCare, Inc., from late 1997 to June 2000, prior to joining CancerVax in October 2000, where he served as President and CEO from 2000 until its merger with Micromet, Inc. in 2006, when he became Chairman. 
 
Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. from 1971 to 1980, and held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.

Kevin Li, PhD

Chairman of the Board of Directors

D r. Kevin Li is a Managing Partner at LYZZ Capital, a healthcare-focused venture capital/PE fund investing globally in leading biotech and pharmaceutical companies. Kevin has been an active biotech investor in the US and China for more than 15 years. Prior to co-founding LYZZ, he was a partner at DT Capital and HBM BioMed China. Earlier in his career, Kevin was involved in the building and management of several successful biotech companies, including GenoSpectra, Fountain Medical Development, and Amazin Biotech. Dr. Li received his PhD in biology from Indiana University and was a postdoctoral fellow at Stanford University School of Medicine.
 
Dr. Li has been an investor and board member of a number of successful biomedical companies in China and the US, such as Nuokang Biopharma, Cathay Industrial Biotech, Xili Pharma, Wuhan Hiteck Biopharma, Chipscreen, Alpha Biopharma, Neurelis, Qpex, iGenomX, and Jumpcode, among others.

Dr. Huaizheng Peng

Director

D r. Huaizheng Peng serves as General Manager of International Investment and Operations for China Medical System Holdings, a specialty pharmaceutical company listed on the Hong Kong Stock Exchange. He is in charge of international operations for the company, including pharmaceutical asset acquisition/product licensing-in/out, international business development, outbound investment, and asset management, among others.
 
Dr. Peng was a partner of Northland Bancorp, a private equity firm. Before that, he worked as a head of life sciences and as a director of corporate finance at Seymour Pierce, a London-based investment bank and stockbroker. Earlier in his career, Dr. Peng was a senior portfolio manager, specializing in global life science and Asian technology investment at Reabourne Technology Investment Management Limited.
 
Dr. Peng received his bachelor´s degree in medicine from Hunan Medical College (now Central South University Xiangya School of Medicine) in Changsha, Hunan Province, China, and he subsequently obtained a master´s degree in medicine from Hunan Medical College. Dr. Peng was awarded his PhD in molecular pathology from University College London (UCL) Medical School, London, UK, and subsequently practiced as a clinical lecturer there.

All trademarks are the property of their respective owners.